Current and evolving understanding of atypical chronic myeloid leukemia

Atypical chronic myeloid leukemia (aCML) is a BCR –ABL1 negative myelodysplastic (MDS)/myeloproliferative (MPN) neoplasm with poor overall survival. The current 2016 WHO classification of myeloid neoplasms allows clinicians to more accurately differentiate aCML from its similar MDS/MPN overlap and MPN counterparts. In addition, the advent of next -generation sequencing has expanded our understanding of the molecular pathogenesis of aCML and its therapeutic potential. Hematopoietic stem cell transplant (HSCT) remains the first consideration in the treatment algorithm for aCML, however, with the advances in mutational analysis, opportunities f or targeted therapy have expanded.
Source: Blood Reviews - Category: Hematology Authors: Tags: Review Source Type: research